At GenEmbryomics, our mission is to empower families to have healthy children by providing patients and providers unparalleled insights into each embryo's genetic disease risks.
We believe in a future where parents will have the knowledge to prevent incurable genetic disease from being unknowingly passed on, and we strive to make that future a reality.
Independent Board Chair
Paul is an accomplished business leader with extensive experience as a non-executive director and chairman of public companies. He has served in multiple executive positions including CEO, COO, CFO, and Company Secretary at various corporations listed on the ASX and NASDAQ. Currently, Paul is Managing Director of Braddon Capital, a globally-focused venture capital firm. There, he specializes in commercialization, corporatization, and mergers and acquisitions, with a focus on emerging deep technologies. His diverse executive and board experience provides valuable strategic guidance as GenEmbryomics scales its operations and expands access to its genomic testing services.
Managing Director, Non-Independent Director
Nick Murphy founded GenEmbryomics after dedicating his career to genetics research and its applications in assisted reproductive technology, immunogenetics, and polygenic risk assessment. With over ten years of experience in the IVF industry, he launched GenEmbryomics to develop innovative genomic testing solutions for embryo screening. The company's flagship test, PGT-WGS, represents the world's first whole genome sequencing-based assay to evaluate embryonic genetic health. With its introduction, PGT-WGS is set to enable improved IVF outcomes for fertility clinics and patients globally. Under Dr. Murphy's leadership, GenEmbryomics continues to leverage the latest genetic technologies to advance the field of reproductive genomics and provide new ways to aid patients struggling with infertility.
Non-Executive, Non-Independent Director
Santiago Munné is an internationally recognized leader in reproductive genetics. Since earning his PhD in Human Genetics from the University of Pittsburgh in 1991, he has published over 200 scientific papers on preimplantation genetic testing, chromosome abnormalities, and personalized infertility diagnostics. Dr. Munné frequently lectures globally and co-founded the Preimplantation Genetic Diagnosis International Society, serving as President and board member. He is the CIO at Overture Life and is the founder of multiple genomics companies including Reprogenetics, Recombine, Phosphorus, MedAnswers, and G1 Sciences. His groundbreaking research and innovations in the field of reproductive and infertility genetics have positioned him as a pioneer in genetic testing and infertility treatment.
Independent Non-Executive Director
Nick is a highly qualified and contemporary independent Non-Executive Director and Audit and Risk Committee Chair, with strong ASX and NASDAQ listed entity expertise and an exemplary professional career spanning over 30 years. Nick’s expertise is sought across a wide breadth of industry sectors encompassing, genetics and life sciences, aquaculture, FMCG, water and sewerage, infrastructure, advanced manufacturing, renewable energy, drone technology, forestry public transport, agribusiness, tourism and hospitality and the visitor economy, education and the VET sector, civil engineering / construction, and finance / valuations. Nick is a Fellow of the Australian Institute of Company Directors, the Institute of Chartered Accountants of Australia, the Governance Institute of Australia, the Tax Institute of Australia and the Financial Services Institute of Australasia
Managing Director
Head of Technology
Governance Officer
Our mission is to maximize successful pregnancy outcomes for patients through cutting-edge embryo screening technology. We are committed to continuous innovation in the field of preimplantation genetic testing to provide unparalleled insights into embryo health and viability.
GenEmbryomics utilizes the latest next-generation sequencing platform to generate comprehensive embryo genetic profiles. Our proprietary bioinformatics pipeline is specially designed for embryo analysis, evaluating variants, and gene expression to assess viability.
GenEmbryomics' industry-leading PGT-WGS testing enables unparalleled accuracy in embryo selection, dramatically improving outcomes for IVF patients. Our pioneering research and advanced AI techniques are redefining the standard of care, achieving the best possible results for hopeful parents.
While other companies offer partial testing, that wasn't good enough for GenEmbryomics. We're here to make a real-world difference to hopeful parents and prevent the unnecessary tragedies of genetic diseases. Our team is committed to offering the highest value testing available globally.
— Dr. Nick Murphy - Founder of GenEmbryomics —
GenEmbryomics is proud to partner with industry leaders Qualio and Compliancy Group to ensure the highest standards of quality and compliance.
